Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure | Zendy

Daniel B. Mark | Zendy; Charlotte Nelson | Zendy; Kevin J. Anstrom | Zendy; Sana M. AlKhatib | Zendy; Anastasios A. Tsiatis | Zendy; Patricia A. Cowper | Zendy; Nancy E. ClappChanning | Zendy; Linda DavidsonRay | Zendy; Jeanne E. Poole | Zendy; George Johnson | Zendy; Jill Anderson | Zendy; Kerry L. Lee | Zendy; Gust H. Bardy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure

Author(s) -

Daniel B. Mark,

Charlotte Nelson,

Kevin J. Anstrom,

Sana M. AlKhatib,

Anastasios A. Tsiatis,

Patricia A. Cowper,

Nancy E. ClappChanning,

Linda DavidsonRay,

Jeanne E. Poole,

George Johnson,

Jill Anderson,

Kerry L. Lee,

Gust H. Bardy

Publication year - 2006

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.105.581884

Subject(s) - medicine , amiodarone , cost effectiveness , heart failure , placebo , cardiology , quality adjusted life year , emergency medicine , atrial fibrillation , risk analysis (engineering) , alternative medicine , pathology

In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), implantable cardioverter-defibrillator (ICD) therapy significantly reduced all-cause mortality rates compared with medical therapy alone in patients with stable, moderately symptomatic heart failure, whereas amiodarone had no benefit on mortality rates. We examined long-term economic implications of these results.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research